Synapsinostat

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Synapsinostat, also known as CN13, is a histone deacetylase (HDAC) inhibitor and possible cognitive enhancer. It potently inhibits the class I HDAC1, HDAC2, and HDAC3, with values of 39 nM, 41 nM, and 100 nM, respectively, whereas other HDACs were not assessed. The drug has been found to potently promote synaptogenesis in vitro.

Synapsinostat was first described in the scientific literature by 2009. Subsequently, other improved analogues acting as HDAC inhibitors such as crebinostat and neurinostat, which show much greater potency, were described.

Synapsinostat, also known as CN13, is a histone deacetylase (HDAC) inhibitor and possible cognitive enhancer. It potently inhibits the class I HDAC1, HDAC2, and HDAC3, with values of 39 nM, 41 nM, and 100 nM, respectively, whereas other HDACs were not assessed. The drug has been found to potently promote synaptogenesis in vitro.

Synapsinostat was first described in the scientific literature by 2009. Subsequently, other improved analogues acting as HDAC inhibitors such as crebinostat and neurinostat, which show much greater potency, were described.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1369621554 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.